# 英國GSK以106億美元收購美國癌症公司Nuvalent，為其第二大交易。

*biotech · news · 2026-06-09 · CNBC TV18*

## Key points

- GSK以106億美元收購Nuvalent，為其第二大交易。
- Nuvalent帶來三款肺癌藥物，其中兩款正處於FDA後期審查階段，加入GSK產品組合。
- 扣除Nuvalent現金後，GSK淨投資為94億美元。
- 這是執行長Luke Miels自2026年1月接任GSK首席後的首筆重大交易。
- Nuvalent的主力藥物Zidesamtinib和neladalkib若獲FDA批准，可能於2026年上市。

Britain's GSK buys US cancer firm Nuvalent for $10.6 billion in its second-largest deal ever Britain's GSK is acquiring US cancer biotech Nuvalent for $10.6 billion, adding three lung cancer therapies to its portfolio as new CEO Luke Miels makes his first major acquisition move. By Vivek Dubey Britain's GSK on Tuesday agreed to acquire Nuvalent, a US-based biopharmaceutical company, for $10.6 billion. Under the deal, GSK will pay $124 per share in cash, representing a 40% premium to Nuvalent's closing share price on Monday. Net of cash acquired, GSK's total investment is estimated at $9.4 billion. The transaction is expected to close in the third quarter of 2026, as per the company statement. The all-cash acquisition is GSK's first major deal under Chief Executive Officer Luke Miels, who took charge in January. It is also among the company's largest acquisitions since its 2014 asset swap with Novartis, under which GSK acquired Novartis' vaccines business in a transaction valued at about $20 billion. Nuvalent's shares had fallen about 12% this year before the deal announcement, leaving the Nasdaq-listed company with a market value of nearly $7 billion. The acquisition comes as global pharmaceutical companies face uncertainty over US trade and pricing policies. Last year, US President Donald Trump threatened tariffs on pharmaceutical imports as part of efforts to encourage domestic manufacturing and lower drug prices. Three Drugs, One Deal The acquisition brings GSK three lung cancer therapies in a single transaction. Two — zidesamtinib and neladalkib — are in late-stage development and already under review by the US Food and Drug Administration, with decision dates set for September 18 and November 27, 2026 respectively. Both drugs have received FDA Breakthrough Therapy and Orphan Drug designations. The third asset, NVL-330, is a HER2 inhibitor in Phase I trials for HER2-altered non-small-cell lung cancer (NSCLC). NSCLC is the most common form of lung cancer and is characterised by genetic mutations in ALK, ROS1, or HER2. Zidesamtinib targets ROS1 mutations and neladalkib targets ALK mutations. Both conditions primarily affect non-smokers between the ages of 40 and 50. "The two lead products are potential best-in-class assets that could launch this year if approved by the FDA," said GSK CEO Luke Miels. Miels' First Big Bet The Nuvalent deal is the first major acquisition for Miels, who took over from Emma Walmsley in January 2026 after she served nearly nine years as CEO. Miels was previously GSK's chief commercial officer. GSK returned to the oncology space in 2019 after a long absence, and this deal marks a significant step in rebuilding that franchise. It also complements GSK's B7-H3 antibody-drug conjugate Ris-Rez, currently in Phase III development, which the company sees as a platform for broader expansion in lung cancer. In January 2026, GSK separately acquired US biotech Rapt Therapeutics for $2.2 billion to build out its immunology and inflammatory disease pipeline. "GSK's proven track record, infrastructure, and expertise will support the successful commercialisation of zidesamtinib and neladalkib, as well as accelerate advancement of our broader discovery pipeline," said Nuvalent CEO James Porter.

**Companies:** GSK, Nuvalent
**Countries:** United Kingdom, United States

[Read the full story on CNBC TV18](https://www.cnbctv18.com/business/companies/britains-gsk-buys-us-cancer-firm-nuvalent-for-10-6-billion-in-its-second-largest-deal-ever-ws-l-19922106.htm)

---

Canonical: https://newsio.io/zh-TW/n/dde7d72d-3159-417b-b118-3b66531c95a3/gsk106nuvalentgsk124nuvalent40
Summarized by Newsio from CNBC TV18. https://newsio.io/how-it-works